BY MIKKEL AABENHUS HEMMINGSEN
-
GLP-1 sales accounted for 75% of Novo Nordisk’s Q2 revenues
Novo Nordisk provided its economic outcomes for the 2nd quarter of 2024 on Wednesday early morning.
-
Novo Nordisk and Eli Lilly need a profit beat to take back market momentum
While Lilly and Novo shares have actually dropped this month in addition to much of the marketplace, they still trade at a considerable rate costs to the remainder of the pharma ma…
-
Urban digital transformation: Insights for marketers from global smart cities
Cities globally are rebranding with electronic makeover, providing marketing experts understandings right into innovation and cutting-edge narration.The message Urban electronic ma…
-
Eli Lilly reports surprisingly strong obesity and diabetes performance
Sales of Mounjaro and Zepbound in the United States were favorably influenced by supply accumulation.
